News Archive

Qiagen has announced plans to launch a new digital test for COVID-19 antibodies that can run multiple samples at once on a small portable device and deliver results in about 10 minutes. 

With a small digital hub and interchangeable testing stick system, the eHub was developed for use against the novel coronavirus in collaboration with Australian diagnostic developer Ellume. The device can process up to eight samples simultaneously, or up to 32 tests per hour, to detect the presence of IgA, IgM or IgG antibodies in plasma or serum.

CAMBRIDGE, Md. and LONDON, Aug. 26, 2020 (GLOBE NEWSWIRE) — OS Therapies, and late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors today announced the co-exclusive licensing of BlinkBio’s novel Si-Linker and Cassette Payload technologies, and exclusive licensing of the BlinkBio technology to target Folate Receptor Alpha (FRα) for tumors and other targeted diseases.

GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the 2023 annual meeting of stockholders. Mr. White was also appointed as a member of both the Scientific Review Committee and Strategic Operations Committee of the board.

Humans are not the only species facing a potential threat from SARS-CoV-2, according to the results of a study by an international scientific team headed by researchers at the University of California, Davis (UC Davis). Using genomic analysis to compare the amino acids of a key part of the ACE2 protein that is used by SARS-CoV-2 to gain entry into human cells, with those of the ACE2 protein in more than 400 other animals, the team found it feasible that many different species, including some, like the Western lowland gorilla, which are highly endangered, could potentially be infected by the virus.

Image: Western lowland gorilla (Trisha Shears/FreeImages)

The United States aims to invest $765 million over the next 5 years in a dozen scientific centers dedicated to the study of artificial intelligence (AI) and quantum information science (QIS), such as quantum computing, the White House announced today. Numerous private tech companies such as IBM, Google, and Intel will also contribute to the twin pushes, which call for a total of more than $1 billion in research investment.

SOMERSET, N.J. – Aug 24, 2020 — Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland.

Don’t miss your change to be named the BioHealth Startup with the Most Commectial Potential at the BHCR Forum, win $10,000 and more!

Applications due: 9/15

Finalists notified by: 10/2

Mandatory presenter coaching for finalists: 10/7

Don’t miss your chance to be named the BioHealth Startup with the Most Commercial Potential at the BHCR Forum, win $10,000 and more!

CONSIDERATIONS:

• Technical Feasibility and IP
• Commercialization and Marketing Strategy
• Leadership Team and Collaborations
• Funding to Date and Financial Projections

CRITERIA:

• Demonstrated Proof of Concept/MVP
• Have received funding (dilutive/nondilutive)
• Understand regulatory and reimbursement hurdles
• A clear path to market and scalable

PREVIOUS WINNERS:

Sonavex

LifeSprout

Galen Robotics

Floreo

Applications due: 9/15

Finalists notified by: 10/2

Mandatory presenter coaching for finalists: 10/7

3rd Annual BioHealth Capital Region Investor Forum

Ocr 20 – 21st, 2020